Viking Therapeutics registers Phase 1 trial of obesity candidate VK3019Sep 29Trial updateViking Therapeutics, Inc.
Viking closes $225M convertible notes and $297M stock sale after upsized option exercisesSep 28FinancingViking Therapeutics, Inc.Updated
Viking Therapeutics registers Phase 1 study of VK2735 in obese adults without comorbiditiesSep 24Trial updateViking Therapeutics, Inc.
Viking reports positive maintenance data for obesity drug VK2735Sep 22Clinical readoutViking Therapeutics, Inc.
Viking reports Q2 2026 results, VANQUISH trials fully enrolled, oral Phase 3 slated for 4Q26Jul 29Quarterly updateViking Therapeutics, Inc.
Sign in